Also known as: Evista; Keoxifene; LY156758
Raloxifene is a second-generation selective estrogen receptor modulator (SERM) that acts as an estrogen agonist on bone and an antagonist on breast and uterine tissue. It is approved for prevention and treatment of osteoporosis and reduction of invasive breast cancer risk. Mediocon Inc manufactures GMP-compliant Raloxifene at its Aurangabad facility.
| Parameter | Specification |
|---|---|
| CAS Number | 84449-90-1 |
| Molecular Formula | C₂₈H₂₇NO₄S |
| Molecular Weight | 473.58 g/mol |
| Grade | IP / BP / EP / USP |
| Category | Selective Estrogen Receptor Modulator (SERM) |
| Assay | NLT 98.0% |
| Loss on Drying | NMT 0.5% |
| Heavy Metals | NMT 20 ppm |
| Residue on Ignition | NMT 0.1% |
| Microbial Limits | Complies with pharmacopoeia |
| Identification | IR, HPLC Compliant |
| Batch No | RAL/24032026 |
| Mfg Date | MAR 2026 |
| Exp Date | FEB 2031 |
| Packing | 25 kg HDPE drums / as per requirement |
Mediocon Inc is a GMP-certified API manufacturer and bulk pharmaceutical ingredient supplier based in Aurangabad, Maharashtra, India. We specialise in supplying Raloxifene — CAS 84449-90-1 (CAS 84449-90-1) and over 1,000 other Active Pharmaceutical Ingredients, excipients, herbal extracts, and nutraceutical ingredients to pharmaceutical manufacturers worldwide.
Our Raloxifene — CAS 84449-90-1 is manufactured under strict quality management protocols compliant with WHO-GMP, ISO 9001:2015, and major pharmacopoeial standards (IP, BP, USP, EP). Every batch undergoes full analytical testing — identity (IR/HPLC), assay, related substances, residual solvents (ICH Q3C), heavy metals, and microbial limits — before release with a Certificate of Analysis.
Export Markets
Quality & Compliance